Literature DB >> 3492959

Pharmacokinetics of ticarcillin and clavulanic acid (timentin) in relation to renal function.

G L Jungbluth, D L Cooper, G D Doyle, G M Chudzik, W J Jusko.   

Abstract

The disposition of coadministered ticarcillin (3 g/1.73 m2) and clavulanic acid (100 mg/1.73 m2) was examined after a 30-min infusion in 24 noninfected subjects with various degrees of renal function. Noncompartmental pharmacokinetic parameters for the individual compounds were determined from plasma concentrations and urinary excretion rates. All clearances (total, renal, and nonrenal) and urinary recoveries of unchanged drug were found to be linearly related to creatinine clearance (CLCR). The steady-state volume of distribution (9.9 and 12.9 liters for ticarcillin and clavulanic acid) approximated the extracellular fluid space and was not related to CLCR. The half-lives increased with reduced renal function and ranged from 56 to 392 min for ticarcillin and 26 to 266 min for clavulanic acid. The clearances of both drugs decreased proportionately with reduction in renal function, facilitating dosing adjustments based on CLCR. Calculations of expected steady-state maximum and minimum concentrations in plasma using constant doses and an extended dosing interval related to CLCR further rationalized use of the 30:1 drug combination ratio for all patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3492959      PMCID: PMC180615          DOI: 10.1128/AAC.30.6.896

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Pharmacokinetics of ticarcillin in patients with abnormal renal function.

Authors:  M F Parry; H C Neu
Journal:  J Infect Dis       Date:  1976-01       Impact factor: 5.226

2.  Pharmacokinetics and tissue penetration of ticarcillin combined with clavulanic acid.

Authors:  S Bennett; R Wise; D Weston; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

3.  In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin.

Authors:  P A Hunter; K Coleman; J Fisher; D Taylor
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

4.  LAGRAN program for area and moments in pharmacokinetic analysis.

Authors:  M L Rocci; W J Jusko
Journal:  Comput Programs Biomed       Date:  1983-06

5.  Pharmacokinetics of ticarcillin in man.

Authors:  B E Davies; M J Humphrey; P F Langley; L Lees; B Legg; G A Wadds
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Fitting straight lines when both variables are subject to error.

Authors:  D S Riggs; J A Guarnieri; S Addelman
Journal:  Life Sci       Date:  1978 Apr 3-17       Impact factor: 5.037

7.  Ticarcillin vs carbenicillin: clinical pharmacokinetics.

Authors:  R D Libke; J T Clarke; E D Ralph; R P Luthy; W M Kirby
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

8.  In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates.

Authors:  P C Fuchs; A L Barry; C Thornsberry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

9.  Pharmacokinetics and serum bactericidal activity of ticarcillin and clavulanic acid.

Authors:  G Höffken; H Tetzel; P Koeppe; H Lode
Journal:  J Antimicrob Chemother       Date:  1985-12       Impact factor: 5.790

10.  Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment.

Authors:  A Mangione; F D Boudinot; R M Schultz; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

View more
  3 in total

1.  Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin.

Authors:  B E Davies; R Boon; R Horton; F C Reubi; C E Descoeudres
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.